


**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-030

OTHER REVIEW(S)



**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology**

Date: October 14, 2008

To: Scott Monroe, M.D., Director
Division of Reproductive & Urologic Products

Through: Jodi Duckhorn, M.A. Team Leader
**Patient Labeling and Education Team
Division of Risk Management**

From: Nancy Carothers, BA, RN
Patient Product Information Specialist
**Patient Labeling and Education Team
Division of Risk Management**

Subject: Review of Patient Labeling for TOVIAZ™ (Patient Package Insert), #2

Drug Name(s): TOVIAZ™ (fesoterodine fumarate, extended release tablets)





Application Type/Number: NDA 22-030

Applicant/sponsor: Pfizer

OSE RCM #: 2008-810

RESPONSE TO SPONSOR'S REVISIONS TO THE PPI:

Please see our response the sponsor's revision of the TOVIAZ PPI:

1. If the sponsor _____ we recommend the term "doctor." One term should be used consistently throughout the PPI. We recommend against the term "healthcare professional" as it is not generally understood.
2. We defer to the Review Division on the question of whether TOVIAZ inhibits or induces enzymes involved in the metabolism of other drugs.
3. We recommend retaining the bullet, ' _____ [doctor] may give you a lower dose if you have certain medical conditions such as severe kidney problems.' The PI states in three sections (Pharmacokinetics in Special Populations, Dosage and Administration, and Precautions) that TOVIAZ is not recommended for patients with severe renal insufficiency at doses higher than 4 mg. This bullet provides additional safety information concerning the patient's medical condition (severe renal insufficiency) and the recommended dosing of TOVIAZ. It is important for these patients to understand clearly that a higher dose is not recommended, especially if their renal problems change from less serious to more serious during their course of treatment with TOVIAZ.
4.   b(4)
5. We agree with listing "constipation" as one of the most common side effects.
6. _____ b(4)
7. The statement, "Safely throw away TOVIAZ that is out of date or no longer needed"  Agam, we 
generally recommend following the Medication Guide regulations as much as possible for consistency across all patient labeling.

MATERIAL REVIEWED FOR THIS RESPONSE:

- TOVIAZ™ PI submitted by the Sponsor on May 1, 2008 and further revised by the reviewing division on September 4, 2008
- TOVIAZ™ PPI submitted by the Sponsor on May 1, 2008 and further revised by the reviewing division on September 9, 2008

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Nancy B Carothers
10/14/2008 02:36:42 PM
DRUG SAFETY OFFICE REVIEWER

Jodi Duckhorn
10/14/2008 03:05:40 PM
DRUG SAFETY OFFICE REVIEWER



DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Pediatric and Maternal Health Staff
Office of New Drugs
Center for Drug Evaluation and Research
Food and Drug Administration
Silver Spring, MD 20993
Tel 301-796-0700
FAX 301-796-9744

Maternal Health Team Review

Date: September 8, 2008 **Date Consulted:** June 27, 2008

From: Richardae Araojo, Pharm.D.
Regulatory Reviewer, Maternal Health Team (MHT)
Pediatric and Maternal Health Staff

Tammie Brent, RN, MSN
Regulatory Reviewer, Maternal Health Team (MHT)
Pediatric and Maternal Health Staff

Through: Karen Feibus, MD
Team Leader, Maternal Health Team (MHT)
Pediatric and Maternal Health Staff

Lisa Mathis, MD
Associate Director, Pediatric and Maternal Health Staff

To: Division of Reproductive and Urologic Products (DRUP)

Drug: Toviaz (fesoterodine fumarate) tablets; NDA 22-030

Subject: Pregnancy and Nursing Mothers labeling

Materials Reviewed: Pregnancy and Nursing Mothers subsections of Toviaz labeling.

Consult Question: This request is for a labeling consult for NDA 22-030. Please review the Pregnancy and Nursing Mothers subsections of labeling.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.